HIGHLIGHTS
- who: María Dolores Martínez-Esteban from the University of, Instituto de Investigación Biomédica de (IBIMA), Spain have published the article: Cardio-renal benefits of sacubitril/valsartan in patients with advanced chronic kidney disease: experience in daily clinical practice, in the Journal: (JOURNAL)
- what: The authors examined the effectiveness and safety of treatment with neprilysin inhibition in patients with advanced chronic kidney disease (stage 3b-4). This study shows that sacubitril/valsartan may play a beneficial role in patients who have advanced CKD and HFrEF with a satisfactory safety profile. The aim . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.